Restricted accessResearch articleFirst published online 2009-10
Effect of Peroxisome Proliferator—Activated Receptor Gamma Agonists on Myofibroblast Differentiation and Collagen Production in Nasal Polyp—Derived Fibroblasts
We investigated the effect of transforming growth factor-β1 (TGF-β1) on the differentiation of nasal polyp–derived fibroblasts (NPDFs) and on their production of collagen, and investigated the effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists on the effects of TGF-β1.
Methods:
Primary fibroblast lines were established from 5 human nasal polyp tissues. We activated the NPDFs with TGF-β1 and exposed them to the PPARγ agonists ciglitazone and 15-deoxy-A-prostaglandin J2. The expression of α-smooth muscle actin (α-SMA) and collagen was measured by reverse transcriptase–polymerase chain reactions, immunocytochemical staining, and collagen assays.
Results:
The treatment with TGF-β1 increased the expression of α-SMA and collagen, and expression was markedly attenuated by the PPARγ agonists.
Conclusions:
PPARγ agonists inhibit the differentiation of TGF-β1–activated NPDFs and their production of collagen.
PawliczakRLewandowska-PolakAKowalskiML. Pathogenesis of nasal polyps: An update. Curr Allergy Asthma Rep2005;5:463–71.
2.
WangQPEscudierERoudot-ThoravalFSamadI Abd-AlPeynegreRCosteA. Myofibroblast accumulation induced by transforming growth factor–beta is involved in the pathogenesis of nasal polyps. Laryngoscope1997;107:926–31.
3.
Levi-SchafferFGarbuzenkoERubinA. Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: A role for transforming growth factor beta (TGF-beta). Proc Natl Acad Sci U S A1999;96:9660–5.
4.
BradleyDTKountakisSE. Role of interleukins and transforming growth factor–beta in chronic rhinosinusitis and nasal polyposis. Laryngoscope2005;115:684–6.
5.
LuXLiuZCuiY. The protein expression difference of transforming growth factor betal, matrix metalloproteinases 1,7,9 and tissue inhibitors of matrix metalloproteinases–1 between chronic rhinosinusitis, nasal polyps and normal mucosa tissues [in Chinese]. Lin Chuang Er Bi Yan Hou Ke Za Zhi2005;19:633–5.
6.
LittleSCEarlySBWoodardCR. Dual action of TGF-betal on nasal-polyp derived fibroblasts. Laryngoscope2008;118:320–4.
7.
BardotOAldridgeTCLatruffeNGreenS. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun1993;192:37–45.
8.
ZiouzenkovaOPlutzkyJ. Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett2008;582:32–8.
9.
LenhardJM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels2001;7:249–58.
10.
KnappPJarzabekKBlachnioAZbrochT. The role of peroxisome proliferator–activated receptors (PPAR) in carcinogenesis [in Polish]. Ginekol Pol2006;77:643–51.
11.
TakanoHHasegawaHZouYKomuroI. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des2004;10:2779–86.
12.
KangHJCinnYGHwangSJ. Up-regulation of peroxisome proliferator–activated receptor gamma in perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg2006;132:1196–200.
13.
CardellLOHäggeMUddmanRAdnerM. Downregulation of peroxisome proliferator–activated receptors (PPARs) in nasal polyposis. Respir Res2005;6:132.
14.
LakatosHFThatcherTHKottmannRMGarciaTMPhippsRPSimePJ. The role of PPARs in lung fibrosis. PPAR Res2007;2007:71323.
15.
FrancisGAAnnicotteJSAuwerxJ. PPAR-alpha effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol2003;285:H1–H9.
16.
WangWLiuFChenN. Peroxisome proliferator–activated receptor — Gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-betal in renal interstitial fibroblasts. Mediators Inflamm2007;2007:62641.
17.
BelvisiMGHeleDJBirrellMA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol2006;533:101–9.
GuLZhuYJGuoZJXuXXXuWB. Effect of IFN-gamma and dexamethasone on TGF-beta1–induced human fetal lung fibroblast-myofibroblast differentiation. Acta Pharmacol Sin2004;25:1479–88.
20.
BalakumarPRoseMSinghM. PPAR ligands: Are they potential agents for cardiovascular disorders?. Pharmacology2007;80:1–10.
21.
BeckerJDelayre-OrthezCFrossardNPonsF. Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases?. Fundam Clin Pharmacol2006;20:429–47.
22.
PicardFAuwerxJ. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr2002;22:167–97.
23.
YuanGJZhangMLGongZJ. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol2004;10:1047–51.
24.
IglarzMTouyzRMVielEC. Peroxisome proliferator–activated receptor–alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension2003;42:737–43.
25.
CalkinACGiuntiSJandeleit-DahmKAAllenTJCooperMEThomasMC. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant2006;21:2399–405.
26.
HondaKMarquilliesPCapronMDombrowiczD. Peroxisome proliferator–activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol2004;113:882–8.
27.
SimePJ. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med2008;56:534–8.
